399 related articles for article (PubMed ID: 20500147)
1. Emerging therapies in relapsing-remitting multiple sclerosis.
Marriott JJ; O'Connor PW
Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
3. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
4. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
5. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
7. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
8. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
9. New management algorithms in multiple sclerosis.
Sorensen PS
Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
11. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
12. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
14. Managing MS in a changing treatment landscape.
Duddy M; Haghikia A; Cocco E; Eggers C; Drulovic J; Carmona O; Zéphir H; Gold R
J Neurol; 2011 May; 258(5):728-39. PubMed ID: 21437661
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
17. Current management of relapsing-remitting multiple sclerosis.
Sedal L; Wilson IB; McDonald EA
Intern Med J; 2014 Oct; 44(10):950-7. PubMed ID: 25302718
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
19. Emerging oral drugs for multiple sclerosis.
Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
[TBL] [Abstract][Full Text] [Related]
20. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]